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Objective: Acute tubular necrosis (ATN) secondary to induced warm ischemia (WI) results in inflammatory and delayed
fibrotic processes and remains a common clinical problem with serious consequences. Because tumor necrosis factor-
(TNF-) is a prominent proinflammatory factor implicated in the pathophysiology of acute renal ischemia reperfusion
injury (IRI), we hypothesized that FR167653 (FR), a potent inhibitor of TNF- and interleukin-1 production, may
reduce IRI.
Methods: IRI was induced in male pigs by bilateral clamping of the renal pedicle for 90 minutes (WI90), or unilateral renal
clamping (90 minutes) after contralateral nephrectomy (1/2N90), or unilateral renal clamping without contralateral
nephrectomy (WIuni90). FR was administered intravenously 60 minutes before WI (1 mg/kg/h), during WI, and
continuously for 3 hours (1 mg/kg/h) during reperfusion in treated groups (FRWI90, FR1/2N90, or FRWIuni90).
Blood and urine samples were collected between day 1 and 3 months after reperfusion for assessment of renal function.
Kidneys were excised and renal tissues were collected at 3 months for morphologic and inflammation evaluation and
protein analysis. Experimental groups were compared with sham operated (control) and heminephrectomized (Unif)
groups without renal ischemia.
Results:ThreeWI90 animals (43%) and five 1/2N90 (70%) were euthanized and necropsied at day 7 because of no urine
production or poor conditions. Mortality was significantly improved after FR treatment. Survival was 100% in the
control, Unif, WIuni90, and FR groups. In Unif groups, FR significantly reduced renal failure and bilateral renal
ischemia (P< .05). At 3months, proteinuria was significantly reduced in FR-treated groups (P< .01). Inflammatory cells
count was also dramatically diminished in FR-treated pigs (P< .01 for CD3-positive cells). The second aspect of transient
ischemia is the fibrotic process determined at 3 months. FR treatment was characterized by a reduction of renal fibrosis,
particularly in Unif groups. TNF- protein expression was diminished in FR-treated groups.
Conclusion: This is the first evidence that FR reduced the early and long-term effect of WI in the severe ischemia model.
This effect was particularly marked against fibrosis and inflammation, which would contribute to deterioration of a
patient’s renal function. (J Vasc Surg 2009;49:728-40.)
Clinical Relevance: Acute ischemia of the kidney is common in the setting of renal artery or aortic surgery. Deterioration
in renal function is a common cause of morbidity in patients treated surgically for juxtarenal and suprarenal abdominal
aortic aneurysms. FR167653 represents a useful therapeutic approach to prevent renal damage in a planned period of
warm ischemia and during suprarenal aortic surgery.Despite many advances in vascular surgery, the incidence
and attendantmortality and globalmorbidity of postoperative
ischemia and reperfusion injury (IRI) is especially high for
patients who undergo major aortic surgery.1 The repair of
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728complex aneurysms and surgeries requiring temporary total or
partial renal ischemia increases IRI.1-3
Acute kidney injury, as encountered in suprarenal aortic
clamping and reperfusion and shock from any cause, is
associated with unacceptability high morbidity that can
range from 40% to 60%. The etiology of acute kidney injury
is diverse and IRI, due to the microvascular blood flow
reduction, is the major cause.4 Like other pathologic con-
ditions of the kidney, renal ischemia may ultimately
progress to chronic advanced kidney disease characterized
by tubule and capillary loss as well as regional interstitial
fibrosis related to chronic hypoxic stress.5-8 IRI is associ-
ated with tubulointerstitial inflammation, which is charac-
terized by an influx of leukocytes early after reperfu-
sion.6-12 The ischemic proximal tubular epithelium can
generate a number of mediators that potentiates the
inflammatory response. These include cytokines such as
tumor necrosis factor (TNF) or interleukin-1 (IL-1),
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transplanted kidneys.13,14
A strong link has been established between TNF-
production and oxidative stress during the IRI process.13,14
The underlying mechanisms appear to involve TNF- pro-
duction by resident renal cells, and the molecular switch
that links ischemia with inflammation involves TNF- by
activating the p38 mitogen-activated protein kinase (p38-
MAPK) pathway.13-16 The MAPK pathway, and particu-
larly p38-MPK, is a key inflammatory mediator that acts by
inducing chemokine/cytokine gene expression.14
The p38-MAPK inhibitor FR167653 (FR; C24
H18FN5O2.H2SO4.H2O; 1-[7-(4-fluorophenyl)-1,2,3,4-
tetrahydro-8-(4-pyridyl)pyrazolo[5,1-c][1,2,4]triazin-2-yl]-
2-phenylethanedione sulfate monohydrate; Fig 1) was
demonstrated to ameliorate IRI of the kidney potentially by
reduced production of inflammatory cytokines (TNF-,
IL-1) that may contribute to damage to the ischemic
kidney and the distant organs. Recently, the underlying
mechanism for FR protection was attributed to the selective
inhibition of phosphorylation of p38-MAPK without af-
fecting the activities of other proteins, such as extracellular
signal-regulated kinase-1, c-JunNH2-terminal kinase-2, or
protein kinase A, C, or G.17-19
Previous studies have described that FR markedly ame-
liorated renal IRI, possibly by inhibiting cytokine/chemo-
kine expression.20-22 These preliminary studies evaluated
the effect of FR after WI for 60 minutes and contralateral
nephrectomy and for a follow-up limited to 7 days after
reperfusion. Ischemic acute kidney injury is a self-healing
disease, but only to a limited extent, and exceeding this
extent results in irreversible loss of renal function.
Nephron mass seems to be a critical long-term prog-
nostic factor. We have developed different models mimick-
ing the early and long-term effect of renal IRI with inflam-
matory process and fibrosis development, which are pivotal
Fig 1. Chemical structure of FR167653: 1-[7-(4-fluorophenyl)-
1,2,3,4-tetrahydro-8-(4-pyridyl)pyrazolo[5,1-c][1,2,4]triazin-2-
yl]-2-phenylethanedione sulfate monohydrate.events.23-26 We initiated the current study to simulateclinical renal ischemia and to focus on the potential use of
FR for operations with a planned period of WI, such as
renal artery bypass, juxtarenal or suprarenal aortic aneurysm
repair, and thoracoabdominal aortic aneurysm repair. We
studied the effect of a severe model of WI (90 minutes) in
the conditions of bilateral renal ischemia and unilateral
renal ischemia, with or without contralateral nephrectomy,
which represent different patient populations exposed to
renal ischemia and delayed renal function recovery. These
models also allow studying the influence of nephron mass
in these conditions and the pure effect of ischemia and
reperfusion.
METHODS
Surgical procedures and experimental groups.
Male pigs (Strain Large white; INRA, Le Magneraud,
Surgères, France) were prepared as previously described.23
Prolonged WI was induced by clamping the renal pedicle
for 90 minutes with a vascular nontraumatic clamp. To
simulate the planned period of WI and different nephron
mass conditions, three experimental groups were studied:
pigs with bilateral renal ischemia lasting 90minutes (WI90,
n  7), pigs with unilateral WI and contralateral nephrec-
tomy (50% of nephron mass reduction, 1/2N90, n 7),
and pigs with unilateral WI without contralateral nephrec-
tomy (WIuni90, n  7). These two last groups were
designed to assess the effect of nephron mass after WI.
After removal of the renal clamp, the kidneys were
inspected for adequate reperfusion. No immediate renal
artery thrombosis was observed. When the contralateral
kidney was retained in place, it was left undisturbed in situ.
FR was administered intravenously before WI (1 mg/
kg/h; 60 minutes before WI induction) and continuously
during WI and for 3 hours (1 mg/kg/h) immediately after
clamp removal in treated groups (FRWI90, FR1/2N90,
and FRWIuni90). The control groups received saline solu-
tion. The doses and rational protocols were based on previous
studies (Supplementary Figures 1 and 2).
These experimental groups were compared with a uni-
nephrectomy group (Unif; n 7, matched by age, weight,
and nephronic mass) and a control group (control; n  7,
matched by age and weight). All experiments were done in
accordance with the Guidelines of the French Agricultural
Office and the legislation governing animal studies.
Functional parameters. The pigs were placed in a
cage to allow specific 24-hour urine collections as previ-
ously described.23-26 Plasma and urinary creatinine (Cr)
was measured enzymatically (Modular, Roche, Meylan,
France), and the concentration of urinary proteins was
determined using a photometry method (Modular,
Roche).
Histopathologic studies. After WI and reperfusion,
kidney samples were collected by ultrasound-guided biopsy
at day 1, day 7, and day 14. At 12 weeks after reperfusion,
survival animals were euthanized and kidneys were re-
moved and sampled for different studies. Samples were
fixed with Duboscq-Brasil and 10% formalin in phosphate
buffer (0.01 mmol/L; pH 7.42) and embedded in paraffin.
min
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periodic acid-Schiff).
The magnitude of tubular epithelial cell loss, necrosis,
intratubular debris, and tubular cast formation was scored
into six levels on the basis of the percentage of affected
tubules in a high-power field under light microscopy, as
previously described27: 0 (no abnormality), 0.5 (10%), 1
Fig 2. Effect of FR167653 (FR) treatment on renal fu
function in the experimental groups after different warm
uninephrectomized (Unif) group. Serum creatinine was
and 12 after WI induction. The values reported are the m
unilateral renal clamping after contralateral nephrectomy
groups vs no-FR-treated groups, °P  .05 FR-treate
1/2N90.
Fig 3. Effect of FR167653 (FR) treatment on proteinu
injury in the different experimental groups after differen
uninephrectomized (Unif) group. The values reporte
FR-treated groups vs no-FR-treated groups. 1/2N90
nephrectomy; WIuni90, unilateral warm ischemia for 90(10%-25%), 2 (25%-50%), 3 (50%-75%), and 4 (75%). Allsections were examined under blind conditions by a pathol-
ogist and a nephrologist, and photographed. Tubular atro-
phy was scored using the same scale. Another lobe of tissue
was removed and shock-frozen in liquid nitrogen and
stored at 80°C.
Immunohistochemical staining of inflammatory
cells and fibrosis. Frozen and paraffin-embedded kidney
. Serum creatinine was determined as a marker of renal
emia (WI) and compared with a control group and an
ured before and at days 1, 2, 3, 7, and 14 and at week 1
 standard error of the mean. 1/2N90, 90 minutes of
ni90, unilateral WI for 90 minutes. *P .05 FR-treated
ups vs no-FR-treated groups, and #FR1/2N90 vs
roteinuria was determined in urine as a marker of renal
ischemia (WI) and compared with control group and
the mean  standard error of the mean.*P  .05,
minutes of unilateral renal clamping after contralateral
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isch
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formed at day 7, and a supplementary biopsywas performed at
6 weeks and 3 months. Sections were deparaffined, rehy-
drated, and heated in a pressure cooker containing citrate
buffer (pH 6) the to boiling point for 2 minutes. The
Fig 4. Effect of FR167653 (FR) treatment on renal
epithelium necrosis, (B) intratubular debris, and (C) c
injury in all categories, whereas the FR-treated group
repair process as shown by evaluation of tubular injury
error of the mean. 1/2N90, 90 minutes of unilate
uninephrectomized group; WIuni90, unilateral warm
no-FR-treated groups.sections were then cooled, rinsed in phosphate-bufferedsaline, and processed for indirect immunohistochemistry,
as previously described.17,18 Inflammation was determined
by evaluation of CD3-positive cells (1:150; Dako,
Glostrup, Denmark) in renal tissue. For positive controls,
antibodies were used in frozen sections of porcine abdom-
lar injury. Tubular injury was defined as (A) tubular
ss. The no-FR-treated groups have very severe tubular
wed mild injury accompanied with a fast and efficient
eek 12. The values reported are the mean  standard
nal clamping after contralateral nephrectomy; Unif,
emia for 90 minutes.*P  .05, FR-treated groups vstubu
ell lo
s sho
at w
ral re
ischinal lymph nodes (data not shown). Negative controls were
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mary antibody (data not shown). All sections were exam-
ined under blind conditions by a pathologist and a neph-
rologist and photographed. The positive cells were counted
in at least 10 corticomedullary fields.
A standard procedure was used as described previously
to estimate the level of tubulointerstitial fibrosis using
picrosirius staining as recommended.28,29 Picrosirius red–
positive staining has been used for nearly 30 years, and the
use of computerized-assisted quantification of fibrosis in
the picrosirius red–stained renal allograft biopsies appears
to be a surrogate marker to predict long-term allograft
function.28 In the current model, picrosirius red staining is
also a useful tool to both analyze and quantify injuries that
could predispose to chronic disease.
Western blotting procedure. Western blot analysis
was performed for protein immunodetection,. as described
previously.24,25 Protein determination was performed 3
months after reperfusion in survival animals (cortical andouter
medulla mainly) at the day of euthanasia. Minced tissue was
placed in extraction buffer (1  tissue extraction buffer;
60mM Tris-base (2-amino-2-hydroxymethyl-propane-1,3-
diol; pH 6.8), 10% glycerol, and 3% sodium dodecyl sulfate
(SDS) containing 5% 	-mercaptoethanol and the protease
Fig 5. Effect of FR167653 (FR) on renal tubular in
arrow points to brush border (bb) integrity. A,Uninep
not treated with FR167653: WI for 90 minutes (WI90
(1/2N90), unilateral WI for 90 minutes (WIuni90),
with FR: FRWI90, FR1/2N90, FRWIuni90, and
200; scale bar, 200 m).inhibitor Antagosan (Hoechst, Paris, France), which wereadded just before use. Tissues were immediately disrupted
with an Ultra Turrax (IKA, Staufen, Germany) homogenizer
at maximum speed for 1 minute on ice, and homogenates
were centrifuged at 26,500g for 15 minutes at 4°C. Superna-
tant aliquots were stored at –20°C for no longer than 1 week
before use.
Equal amounts of proteins (50 to 100 g) were
separated on SDS–polyacrylamide gels (12% or 4%-20%)
under reducing conditions and electrophoretically trans-
ferred onto polyvinylidene difluoride membranes (Bio-
Rad, Hercules, Calif). Membranes were blocked for 1
hour in Tris-buffered saline Tween-20/5% nonfat milk
and incubated overnight at 4°C with antibodies against
TNF-, (1:200, Santa Cruz Biotechnology, Santa Cruz,
Calif). Anti-p38-MAPK and antiphospho p38-MAPK
(Cell Signaling Technology, Danvers, Mass) were used for
their cross reactivity against pig tissue and the ratio was
determined. Total proteins in the extract in each condition
were measured by the BCA protein assay kit with bovine
serum albumin as a standard. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; 1:10,000; Trevigen Inc) or actin
(1:1,000; neoMARKERS Inc, Fremont, Calif) was used as
a loading control. Intensities of the protein bands (dupli-
cate for each animal) were determined using densitometry,
fter warm ischemia (WI) and reperfusion. The black
omy (Unif) group. B, Control group. C to F, Groups
ilateral renal clamping after contralateral nephrectomy
Iuni90 contralateral kidneys. G to J, Groups treated
Iuni90 contralateral kidneys (original magnificationjury a
hrect
), un
and W
FRWquantified, and averaged.
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green for TNF-. At 3 months after reperfusion, TNF-
messenger RNA (mRNA) in the cortex and outer medulla
was measured to assess the influence of FR treatment, as
previously described.19 The primer sequences for PCR
were as follows: TNF-; upstream 5=-TCCTCACTCA-
CACCATCAGC-3=, downstream, 5=-CCAAAATAGAC-
CTGCCCAGA-3=. The relative amount of mRNA, nor-
malized to an internal control 18S rRNA (primer
sequences: forward, 5=-CGTCCCCGCCCCTTGCCTCT-
3=, reverse 5=-GCTTTCGCTCTGGTCCGTCTT-3=) and
Fig 6. Effect of FR167653 (FR) treatment on the onse
of kidney areas displaying interstitial fibrosis stained wit
ischemia within kidneys. The values reported are the mea
vs no-FR-treated groups. Lower Panel, Immunostaining
Uninephrectomy (Unif) group and control group, respe
(WI) for 90 minutes (WI90), 90 minutes of unilat
(1/2N90), WIuni90, and WIuni90 contralateral kid
FRWIuni90, and FRWIuni90 contralateral kidneys (origrelative to a calibrator (normal), was calculated by 2–

CT.Real-time quantitative PCR results were quantified and
expressed as the percentage change in copy numbers rela-
tive to the normal group.
Measurement of TNF- and IL-1. Blood samples
were collected from a jugular catheter before WI induction
and at 1, 3, and 24 hours after reperfusion for TNF- and
IL-1 level determination. At 3 months, TNF- was deter-
mined from blood a sample collected directly from a renal
vein. IL-1 was assayed using a commercial enzyme-linked
immunoabsorbent assay kit (Biosource Int, Camarillo,
Calif) following manufacturer’s instruction. TNF- was
ubulointerstitial fibrosis. Upper Panel, The percentage
rosirius was measured during several weeks after warm
tandard error of the mean. *P .05, FR-treated groups
icrosirius in the different experimental groups.A and B,
y. C to F, no-FR167653-treated groups: warm ischemia
uni) renal clamping after contralateral nephrectomy
G to J, FR-treated groups: FRWI90, FR1/2N90,
agnification 200; scale bar, 200 m).t of t
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Statistical methods. Results are shown as mean 
SEM. Comparisons within groups were performed by use
of a paired t test. For the statistical analysis among groups,
we used analysis of variance with Bonferroni correction for
multiple comparisons, followed by an unpaired t test. Sta-
tistical significance was accepted for P  .05.
RESULTS
Effects of FR167653 and warm ischemic injury on
early and long-term renal function and survival. The
outcomes afterWI and reperfusion differ markedly between
groups. Three animals (43%) in the WI90 group and five
(70%) in the 1/2N90 group were euthanized at day 7
because of no urine production or poor condition. During
this procedure, renal pedicle patency was controlled and no
thrombosis was observed. Survival was 100% in control,
Unif, WIuni90, and FR groups (P  .05 vs WI90 and
1/2N90). Renal functional data are shown in Fig 2.
During the first week, the creatinine concentration was
significantly increased in no-FR-treated groups (day 1 to 7
after reperfusion; P  .05) compared with FR-treated
groups (Fig 2). No difference was observed in the WIuni90
groups (with or without FR treatment) because of the
contralateral functional kidney. After 7 days after ischemia,
the creatinine concentration still remained increased in the
reduced nephron mass (1/2N90) group compared with
FR-treated group (14 days and 1 and 3 months after
reperfusion).
At 3 months a significantly high level of proteinuria was
detected in the 1/2N90 and in bilateral renal ischemia
Fig 7. Effect of FR167653 (FR) treatment on tubula
reported are the mean standard error of the mean. *P
minutes of unilateral (uni) renal clamping after contralatergroups (WI90), suggesting the role of residual nephronmass and the level of injury compared with FR-treated
groups (Fig 3). No difference was observed between
groups with unilateral renal ischemia without contralateral
nephrectomy (with or without FR treatment) compared
with the control and Unif groups. In turn, a significantly
high level of proteinuria was detected in the WI90 and
1/2N90 groups compared with the control and Unif
groups. These data suggest that FR is effective to protect
kidneys from IRI consequences even in reduced renal mass,
which represents the patient population particularly ex-
posed to IRI.
Effect of FR167653 and WI on the cellular integ-
rity of post-reperfused kidneys. Histologic analysis of
biopsy samples from WI kidneys revealed differences in the
cellular integrity at day 14 (Fig 4). Biopsy specimens from
no-FR-treated groups (particularly 1/2N90 groups) had
marked injury showing tubular necrosis and tubular casts
compared with FR-treated groups (Fig 4). In turn, FR-
treated groups exhibited limitation of renal injury and a
reduction of renal injury at day 14, suggesting that the
injury level was reduced and the regeneration process was
more efficient. No injury was detected in the control group
and contralateral kidney (not ischemic) in the Wiuni90
groups. Kidneys from the different groups are presented in
Fig 5. In the FR-treated groups, renal damage was reduced
and brush border integrity was well preserved.
Effect of FR167653 on the onset of interstitial
fibrosis and inflammation. Determination of interstitial
fibrosis at 3 months after reperfusion is presented in Fig 6
(upper panel). The more intense percentage of interstitial
fibrosis was observed in no-FR-treated groups, particularly
within the 1/2N90 group (P .05). The lesions in these
phy at 3 months (See Methods for details). The values
R-treated groups vs no-FR-treated groups. 1/2N90, 90
hrectomy;WI, warm ischemia;Unif,Uninephrectomy.r atro
.05, Fgroups exhibited a focal-radial character and are character-
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glomeruli, and vessels (Fig 6, lower panel). In turn, FR
reduced fibrosis development, particularly in all treated
groups, including kidneys exposed to ischemia in the FR-
WIuni90 group. Fibrosis development was accompanied by
marked tubular atrophy in no-FR-treated groups compared
with FR-treated groups (Fig 7). The protective effect of FR
was marked in the 1/2N90 group, which was the more
severe experimental condition.
At 3 months, the major inflammatory cell population
detected by immunohistochemical studies was CD3-
positive (CD3) T lymphocytes. No infiltrating cells
were detected in the control and Unif groups (data not
shown). The number of cells staining CD3 increased in
the no-FR-treated groups, particularly in the 1/2N90
group (Fig 8, upper panel). Increased CD3 cell staining
was also detected in ischemic kidneys from the WIuni90
pigs and some cells were also observed in the contralateral
kidneys. After 4 weeks, CD3 slightly increased in the
no-FR-treated groups. The FR-treated groups exhibited
reduced inflammation, particularly in the FR1/2N90
group at 3 months (Fig 8, lower panel).
Effect of FR167653 on the expression of TNF-
and p38-MAPK phosphorylation in warm ischemic
tissue. At 3 months after reperfusion, FR treatment influ-
enced inflammation in the warm ischemic tissue. This re-
duction of inflammation was accompanied by the modula-
tion of TNF- by FR treatment (Fig 9, A and B: upper
panel). Production of TNF- was predominantly detected
in the WI90 and particularly in the 1/2N90 groups.
Within contralateral kidneys from WIuni90, TNF- was
not detected. FR treatment reduced TNF- expression in
all experimental groups, even in the WIuni90 group within
exposed kidneys. At the end of the 3-month follow-up,
TNF- was also modulated by FR treatment (Fig 9, C,
middle panel). No FR-treated groups showed an increase in
the ratio of TNF- mRNA, particularly in the 1/2N90
group. In WI90 (bilateral renal ischemia model) pigs,
TNF- mRNA remained increase compared with the FR-
treated pigs. In the Wiuni90 group, TNF-messenger was
increased in the ischemic kidneys compared with the FR-
treated group. In the contralateral kidneys, no difference
was noted and the values were at the same level observed in
the control and Unif groups. FR reduced phospho-p38-
MAPK expression in kidney tissue at 3 months (Fig 9, C
and D).
Effect of FR167653 on cytokine release. As ex-
pected, the circulating level of TNF- and IL-1 was atten-
uated in the FR-treated groups (Fig 10). At 3 months, the
circulating level of TNF-was attenuated in the FR-treated
groups and paralleled the renal inflammation (Fig 11).
DISCUSSION
The WI-reflow model results in extensive necrosis that
destroys the proximal tubules of the outer stripe of the
outer medulla and is variable in extent, both with short and
longer periods of obstruction.5,8,28,30-32 The kidney has
the ability to restore the structural and functional integrityof the proximal tubule, which undergoes extensive epithe-
lial cell death after prolonged exposure to ischemia, but
only to a limited extent. This ability is modulated by the
resulting damage levels and the residual functional nephron
mass.33,34 A recent study demonstrated that nephron repair
by surviving tubular epithelial cells is the predominant
mechanism of repair after ischemic tubular injury in the
adult mammalian kidney.35 As a consequence, improving
the ability of the kidney to tolerate ischemic injury would
have important implications in different clinical situations
such as organ transplantation or major aortic surgery for
patients with pre-existing conditions of reduced nephron
mass.
The current study showed FR is effective in improving
renal recovery function, particularly after severe ischemia
(WI for 90 minutes) and contralateral nephrectomy, which
represents severe conditions in the current model. IRI in
the uninephrectomized condition causes further reduction
of nephrons, enough to accentuate the glomerular injury
by glomerular hyperfiltration and hypertension, which fi-
nally promote the development of glomerulosclerosis. In-
jured tissues release cytokines that promote inflammation,
proliferation of fibroblasts, and interstitial fibrosis 36 Inter-
estingly, FR was effective to protect renal tissue from WI
and its consequences when the contralateral kidney was in
place.34,35
The long-term effect of FR is marked by a reduction of
proteinuria excretion at 3 months, accompanied by a
marked reduction of tubulointerstitial fibrosis and a reduc-
tion of tubular atrophy. Several investigators have reported
the development of chronic and progressive renal dysfunc-
tion after severe acute kidney injury, and a review is pre-
sented by Basile.8 Interstitial fibrosis, which is characterized
by accumulation of extracellular matrix protein, is a com-
mon feature of progressive renal diseases and is correlated
with structural damage. These data suggest that FR treat-
ment has the ability to affect the events that lead to fibrosis,
and likely at the initiation phase, by reducing IRI and
protecting the remaining renal mass. The underlyingmech-
anism could be related to the limitation of phosphorylated
p38-MAPK expression, which is involved in the production
of proinflammatory cytokines.
IRI is marked not only by necrosis or apoptosis, or
both, but also by an inflammatory response that may occur
by either antigen-dependent or antigen-independent in-
sults.37,38 Some controversy exists about the role of these
inflammatory cells in the early phase after renal injury.
Inflammation can result in a reduction in local blood flow
to the outer medulla, with adverse consequences on tubule
function and viability.39,40 However, renal and extrarenal
immune responses were recently demonstrated to occur
after a single episode of severe IRI.41 These changes could
in turn have long-term consequences on the progression of
renal disease in transplanted and native kidneys.
In the current study, WI and renal mass influenced
detection of inflammatory cells. FR treatment significantly
lowered cell infiltration in the early and long-term follow-
up, suggesting that this drug attenuates inflammatory pro-
bar,
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ing because IRI is an inflammatory condition that
profoundly affects both early and long-term function of the
kidney, and the acute phase of IRI has been increasingly
viewed as part of the innate immune response.6,15
A number of proinflammatory cytokines and chemo-
kines have been consistently implicated in the pathophysi-
Fig 8. Effect of FR167653 (FR) treatment on inflamma
positively stained cells per surface area was counted on b
at 3 months. FR treatment reduced CD3-positive cell
Immunostaining for CD3-positive cells at 3 months (bla
tomy (Unif) group, and control group, respectively. No
(uni) renal clamping after contralateral nephrectomy (1/
and WIuni90 contralateral kidneys. FR-treated group
contralateral kidneys (original magnification 200; scaleology of acute renal failure, among the most prominent ofwhich is TNF.14 TNF- is implicated in the pathogenesis of
different renal diseases and can promote renal dysfunction
by direct cytotoxicity, vasoconstriction, and inflammatory
cells recruitment.13,35,42,43 Up-regulation of mRNA and
protein levels of TNF occurs at a whole-organ level within
minutes to hours of the onset of IRI.13
FRwas discovered as a cytokine production inhibitor of
in post-reperfused kidney.Upper Panel, The number of
samples from experimental groups at 1 and 6 weeks and
ning compared with no FR treatment. Lower Panel,
row) in the different experimental groups, uninephrec-
67653-treated groups: WI90, 90 minutes of unilateral
90), 90 minutes of unilateral warm ischemia (WIuni90),
WI90, FR1/2N90, FRWIuni90, and FRWIuni90
200 m).tion
iopsy
s stai
ck ar
-FR1
2N
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flammatory mediator that contributes to TNF- produc-
tion at a post-transcriptional step under various condi-
tions.16,22,41 Our study showed FR reduced p38-MAPK
protein expression and TNF- at the messenger and pro-
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Fig 9. Effect of FR167653 (FR) treatment on tumor ne
and on phosphorylated p38-mitogen activated protein k
conditions. A, Representative immunoblots of TNF- f
renal protein. FR treatment reduced TNF- expression.
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p38 and total p-38 respectively. The values reported are t
of unilateral renal clamping after contralateral nephrec
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no-FR-treated groups.
Fig 11. Quantification of circulating tumor necrosis facto
standard error of the mean. 1/2N90, 90 minutes of un
uninephrectomized group; WIuni90, unilateral warm
FR167653 (FR) vs untreated groups, °P  .05 WI andgroups vs control and Unif groups.tein level, accompanied by a limitation of inflammatory
process.
Current data suggest also a potential influence of
nephron mass, which is involved in the IRI process. Ac-
cording with data reported by Cruzado et al,34 our results
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the outcome of the ischemic kidneys. However, we have
observed that bilateral ischemia induces less severe chronic
renal lesions compared with WI associated with contralat-
eral nephrectomy. Exposed nephron mass paralleled with
the TNF- expression within tissue collected from different
experimental conditions. We have also observed that
nephrons were incompletely repaired in the 1/2N90
group. This suggests that the different compensatory
mechanisms are not fully adapted in this condition. The
reduced nephron mass could also be related with a limita-
tion of the surviving tubular epithelial cells involved in the
mechanism of repair after ischemic tubular injury.30,35
Nevertheless, the current study demonstrates that FR is a
renoprotective treatment for the remaining kidney in a
large animal model of IRI.
The results collectively demonstrate that a single ad-
ministration of FR, before WI induction and during the
early stage of reperfusion, is efficient to reach a protective
level against inflammation and fibrogenesis, which are the
two determinants of the progression of renal fibrosis. Such
pharmacologic treatments have a potential indication for
renal protection to safely improve WI tolerance during
open or laparoscopic surgeries, particularly for exposed
patients with reduced nephron mass.
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